In recent years, the field of gene therapy has seen significant advancements, with over 40 cell and gene therapies now approved for human use by the FDA. However, despite the promise of these therapies, their high cost poses a significant barrier to accessibility. Eric Kelsic, CEO of Dyno Therapeutics, believes that artificial intelligence (AI) has the potential to revolutionize gene therapy delivery, ultimately reducing costs to $0.
Kelsic explains that while gene therapies have become safer and more effective, they remain some of the most expensive medicines on the market. By utilizing AI, Dyno aims to optimize the design of adeno-associated virus (AAV) capsids, which are commonly used to deliver genes to target cells. Through the use of AI, Dyno can generate large datasets to identify patterns and insights that lead to the creation of new sequences with improved performance.
Research conducted by Dyno has demonstrated the power of AI in designing synthetic AAV capsids that can bypass pre-existing immunity, thus making gene therapy accessible to a wider range of patients. Moreover, Kelsic believes that AI can lead to significant cost reductions in gene therapy delivery, potentially bringing the cost down to $0 through improvements in delivery efficiency and sequence optimization.
While there are challenges associated with utilizing AI in gene therapy development, such as the need for high-quality data, Dyno has made significant progress in this area. By leveraging AI to optimize gene therapy delivery, Dyno is at the forefront of revolutionizing genetic medicine and making these life-saving treatments more affordable and accessible to patients globally.
Source
Photo credit www.technologynetworks.com
